HemoGenyx Pharmaceuticals PLC (LON:HEMO) found good gains on Wednesday after it said pre-clinical trials in animals indicate its CDX antibody is effective as a conditioning therapy in bone marrow transplants.
Conditioning is a pre-requisite for a transplant but it is extremely toxic and has severe side effects, which reduces the number of people eligible.
In vivo data showed CDX helps the human body’s own defences (T-cells) to target the cancerous cells.
Vladislav Sandler, Hemogenyx’s chief executive, said he was ‘much encouraged by this new data’.
"This new data demonstrates our continuing progress in developing potential uses for our CDX antibody.”
Today’s results are the latest in a string of promising updates about CDX from Hemogenyx.
Over the past two weeks, lab test results showed the antibody was effective against two types of blood cancer: acute myeloid leukemia and acute lymphoblastic leukemia, where transplants are the standard treatment.
In afternoon trading, shares in Hemogenyx were 7.7% higher at 2.80p.
-- Adds share price --